This paper presents chemotherapy scheduling of cancer patients using type 1 and type 2 fuzzy logic controllers which are optimized by genetic algorithm. To handle the uncertainties of the model, we introduce a method to adjust the foot print of uncertainty (FOU) in interval type 2 (IT2) fuzzy systems based on the amount of uncertainty. Based on previous researches, type two fuzzy logic is more effective than type 1 in handling uncertainties in a model. According to this fact, proposed method tries to change the FOU of fuzzy sets adaptively based on the amount of uncertainty in counting tumor cells which always exist in real world. In addition, we have introduced two new indices to evaluate the results. Simulation results show that the proposed method can control the drug regimens better than IT2 and type 1 (IT1) fuzzy controllers.
Introduction
Cancer is one of the most dangerous diseases which causes many deaths every year. Although new medical methods such as gene therapy and immunotherapy have been developed by scientists in recent years, these methods are still in their infancy. Different ways such as surgery, chemotherapy, radiation, and hormone therapy have been used in treatment of cancer. Chemotherapy is still one of the most effective methods in this field although it has many side effects such as toxicity and drug resistance [1] . Therefore the dosage of the therapy must be carefully adjusted in order to cause the minimum damage to healthy tissue whilst killing a maximum number of tumor cells [2] . In this field, feedback control theory can be applied to optimize the dosage of the therapy. Different approaches are introduced in modelling of the growth of tumor and normal cells. Some of these models were based on cellular automata [3] [4] and some of them are introduced based on PDE's and cellular automata [5] [6] .
Mathematical models and control theories can be employed to improve the quality of treatment and obtain systematic strategies of drug delivery. In one of the first efforts in this way, Swan used a logistic growth model to optimize the drug delivery of treatment procedure [7] . Later, Martin developed an optimal controller to schedules the drug delivery for a patients [8] . Competition model of cancer tumor based on immune system response and drug therapy which includes tumor cells, immune cells, host cells and drug interaction has been introduced by Pillis where optimal control theory was used to optimize chemotherapy regimens [9] .Neural network was applied in a study for optimizing drug delivery based on feedback linearization by Floares [10] . Maximizing the effectors cells and interleukin-2 concentration has been considered in drug delivery optimization by Burden [11] . Lyapunov stability theorem has been applied in a closed loop control system proposed by Ghaffari to push the system to the area with smaller tumor cells [12] . Fuzzy logic was also applied in dosage optimization by Khaloozade [13] . Gompertzian model of tumor growth was used in optimization a cost function which considered the number of tumor and healthy cells simultaneously. Recently, a multi approach model introduced by Westman et al [1] has been used by Batmani and Khaloozade [15] . In this model a compartmental model was extended to appropriately describe drug resistance and two constraints were imposed on the value of the anticancer drug dynamics to avoid toxicity [14] . In this paper, we propose a simple method to adjust the footprint of uncertainty (FOU) of IT2 adaptively (called AIT2) based on the amount of uncertainty generated in counting the number of tumor cells. This paper is organized as following. The second section provides an overview to the mathematical frameworks including patient's model and adjustable interval type 2 fuzzy controllers. Proposed model of the system is introduced in the third section. Simulation results are demonstrated in the fourth section and finally conclusions are discussed in the last section.
Mathematical Framework

Westman's Model
In Westman's model each cell has four phases (called G1, S, G2 and M) in its life cycle. In G1, protein and RNA synthesis are active and consequently DNA is produced in phase S. In G2 phase, duplicated chromosomes are condensed and finally nuclear and cytoplasmic divisions occur in phase M. Based on the cell cycle, tumor cells which might be sensitive or resistant to the drug are divided into the two groups P and C in Westman's model. Four compartments are defined which compartments Ps and Pr belong to the group P (sensitive and resistant cells respectively) and compartment Cs and Cr belong to the group C (sensitive and resistant cells respectively).Dynamic equations (1) describe the mathematical models of these compartments and their interactions. (1) is determined by following equation [15] :
where ( ) is drug concentration which can be realized such as ( ) = ( ) − ( ). In this equation = 0.27 is a constant related to the drug elimination rate and ( ) is drug delivery rate which should be less than 2 ⁄ at each cycle of chemotherapy [14] .Total number of tumor cells is calculated by ( ) = ( ) + ( ) + ( ) + ( ).
Healthy Cells
Gompertzian model is considered for the number of healthy cells. Proposed model is as follow [10] : 
Fuzzy Controllers
Fuzzy systems and fuzzy controllers have been widely used in industrial and biological systems. Type-2 fuzzy logic was introduced by Zadeh [15] and has been applied in widespread applications in the recent years [16] [17] [18] [19] . Type-2 fuzzy set is characterized by a type-2 membership function ( , ) such as:
To reduce the computational cost, interval type-2 fuzzy system (IT2-FS) which assumes interval membership grades for each type-2 fuzzy set, has been applied in this work [20] . Similar T2-FLS, the membership functions of IT2-FLS includes an uncertainty area, called footprint of uncertainty (FOU) (Fig. 1) . 
where [0,0.6] is a bounded factor. It is clear that larger gives larger area in FOU. ) and change of error (∆ ) .Fuzzy rules are formed as (7):
Proposed Model
where is drug delivery of rule, and ∆ are IT2 Gaussian membership functions of error and change of error respectively and s are output coefficients of consequent part of the rules. Error and change of error have been calculated every 14, 21 or 28 days after chemotherapy and scaled such that −1 ≤ ≤ 0 and −0.5 ≤ ∆ ≤ 0.5 where are fuzzified by five fuzzy sets VL, L, M, H and VH for each of them (Note: since the number of tumor cells is often more than reference value (10 ), error is a negative value). In this block diagram, it is supposed that the patient model is constructed by mathematical model plus a random uncertainty factor ( ) such that = (1 + ) × , ∈ [−0.5 , 0.5 ] (this is because of some error in counting the tumor cells).
As it is shown in equation (6) 
where and are the number of tumor cells of patient and mathematical model of patient (which is expected to be true) respectively (Fig. 2) . More difference between and causes larger which in turn expands FOU by equation (7). In (8) 
Results
GA has been used to set the unknown parameters of fuzzy model to optimize the following cost function:
where = ∫( − 10 ) , = ∫( ( ) − 10 ) , ( ) is the number of healthy cells in time ′ ′ (equation 3), 10 and 10 are desired amounts of number of tumor and healthy cells respectively (Note: we use logarithmic function in cost function to close and to each other). The weights and are coefficients that according to the patients are determined by physicians and + = 1 . In this paper, we set = 0.95 and = 0.05. IT1 (interval type 1) and IT2 membership functions of variables have been shown in Fig. 3 . Model performance has been evaluated in three different chemotherapy period (14, 21 and 28 days). Type 1 (IT1), interval type 2 (IT2) and adaptive interval type 2 (AIT2) fuzzy models have been compared with two criteria:
(sum of delivered dosage in 84 days) and (rate of tumor cells to normal cells) determined by (18) .
where ( = 84) and ( = 84) are number of tumor and normal cells at the final day.
Tumor and normal cells of three chemotherapy period by IT1 controller are shown in Fig. 4 . With regard to some error in counting the number of tumor cells in real case, the difference between patient's model and mathematical model is shown in this figure. The model is evaluated with three types of controllers IT1, IT2 and AIT2. Since is a uniform random value, all types of controllers are evaluated 30 times and the mean of and are given in table 2. As it is given in table 2, in all cases of controllers, of AIT2 model is less than the others which shows that the adaptive change in FOU could increase the dosage and decrease the number of tumor cells. In addition, the results shown in table 2, illustrate the superiority of IT2 model compared with IT1. 
Conclusion
In this paper, adaptive FOU of type 2 fuzzy model (AIT2) has been considered. We proposed a method to adjust the FOU of membership functions regarded to the uncertainty in the model. Proposed method and new defined indices are evaluated by patient's model under chemotherapy. The performance of IT2 and IT1 models are also compared in this paper. Results show the superiority of AIT2 compared to IT2 and IT1 models. In fact, it is shown that in the selected model, the area of FOU can be adaptively changed regarded to the amount of uncertainty to improve the defined indices. In future, proposed method can be evaluated by other bio or industrial systems. More researches are needed to verify the relation between area of FOU and uncertainty in the industrial model. 
